Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Lantheus stock

Own Lantheus stock in just a few minutes.

Lantheus Holdings, Inc is a diagnostics & research business based in the US. Lantheus shares (LNTH) are listed on the NASDAQ and all prices are listed in US Dollars. Lantheus employs 595 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Lantheus

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LNTH – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lantheus share price

Use our graph to track the performance of LNTH stocks over time.

Lantheus shares at a glance

Information last updated 2021-04-30.
52-week range$10.52 - $23.85
50-day moving average $20.93
200-day moving average $16.50
Wall St. target price$23.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $0.01

Buy Lantheus shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lantheus stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Lantheus under- or over-valued?

Valuing Lantheus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Lantheus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Lantheus's PEG ratio

Lantheus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.61. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Lantheus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Lantheus's EBITDA

Lantheus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $42.2 million.

The EBITDA is a measure of a Lantheus's overall financial performance and is widely used to measure a its profitability.

Lantheus financials

Revenue TTM $339.4 million
Operating margin TTM 5.22%
Gross profit TTM $146.1 million
Return on assets TTM 1.73%
Return on equity TTM -4.29%
Profit margin -3.97%
Book value $7.69
Market capitalisation $1.6 billion

TTM: trailing 12 months

Shorting Lantheus shares

There are currently 2.8 million Lantheus shares held short by investors – that's known as Lantheus's "short interest". This figure is 2.6% up from 2.7 million last month.

There are a few different ways that this level of interest in shorting Lantheus shares can be evaluated.

Lantheus's "short interest ratio" (SIR)

Lantheus's "short interest ratio" (SIR) is the quantity of Lantheus shares currently shorted divided by the average quantity of Lantheus shares traded daily (recently around 609475.27352298). Lantheus's SIR currently stands at 4.57. In other words for every 100,000 Lantheus shares traded daily on the market, roughly 4570 shares are currently held short.

However Lantheus's short interest can also be evaluated against the total number of Lantheus shares, or, against the total number of tradable Lantheus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lantheus's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Lantheus shares in existence, roughly 40 shares are currently held short) or 0.0602% of the tradable shares (for every 100,000 tradable Lantheus shares, roughly 60 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lantheus.

Find out more about how you can short Lantheus stock.

Lantheus share dividends

We're not expecting Lantheus to pay a dividend over the next 12 months.

Lantheus share price volatility

Over the last 12 months, Lantheus's shares have ranged in value from as little as $10.52 up to $23.85. A popular way to gauge a stock's volatility is its "beta".

LNTH.US volatility(beta: 1.21)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lantheus's is 1.2113. This would suggest that Lantheus's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Lantheus overview

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease; Gallium-67 to detect various infections and cancerous tumors; and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer; flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroendocrine tumors; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic; 1404, a Tc-99m labeled small molecule; PSMA-AI, an AI-based imaging analysis technology; and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site